Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn's disease

Journal of Crohn's and Colitis

Volumn 10, Issue 5, 2016, Pages 510-515

  Zittan, E ^a,b   Kabakchiev, B ^a   Milgrom, R ^a   Nguyen, G C ^a   Croitoru, K ^a   Steinhart, A H ^a   Silverberg, M S ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b HAEMEK MEDICAL CENTER   (Israel)

Author keywords

Adalimumab; Crohn's disease; Endoscopic remission

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; METHOTREXATE; ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; COLON MUCOSA; COLON ULCER; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DRUG BLOOD LEVEL; FEMALE; HARVEY BRADSHAW INDEX; HEALING; HUMAN; ILEOCOLONOSCOPY; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOSAL HEALING; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; REMISSION; SENSITIVITY AND SPECIFICITY; ADOLESCENT; BLOOD; CLINICAL TRIAL; COLON; DIAGNOSTIC IMAGING; DRUG MONITORING; ILEUM; INDUCTION CHEMOTHERAPY; INTESTINE MUCOSA; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; COLON; COLONOSCOPY; CROHN DISEASE; CROSS-SECTIONAL STUDIES; DRUG MONITORING; FEMALE; HUMANS; ILEUM; INDUCTION CHEMOTHERAPY; INTESTINAL MUCOSA; LOGISTIC MODELS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84982199930     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw014     Document Type: Article

References (17)

1. Mahil SK, Arkir Z, Richards G, et al. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. Br J Dermatol 2013;169:306-13.
2. Yarur AJ, Rubin DT. Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2015;21:1709-18.
3. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9.
4. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
5. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98.
6. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012;380:1606-19.
7. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54.
8. Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 2015;13:522-30 e2.
9. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33; quiz 591.
10. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9.
11. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40.
12. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014;12:80-84 e2.
13. Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNFalpha therapy: serum levels of infliximab and adalimumab associate with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol October 29, 2015 pii: S1542-3565(15)01492-5
14. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749-53.
15. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
16. Wang SL, Hauenstein S, Ohrmund L, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal 2013;78-79:39-44.
17. Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol 2014;109:1250-6.